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Objective: Cardiac stem cell transplantation as a potential means of regenerating
infarcted myocardium is currently receiving a great deal of interest. However, data
on these endogenous cardiac precursors are primarily derived from animal studies,
and their clinical relevance still remains elusive.
Methods: We prospectively screened 32 endomyocardial biopsies harvested from
heart transplant recipients (off rejection episodes) and 18 right appendage biopsies
collected during coronary artery bypass surgery, and processed the tissue specimens
for the immunohistochemical detection of markers of stemness (c-kit, MDR-1, Isl-1),
hematopoietic origin (CD45), mast cells (tryptase), endothelial cells (CD105), and
cardiac lineage (Nkx2.5). Confocal microscopy was used for colocalization experi-
ments. Three right appendage biopsies were also cultured for 2 to 3 weeks, at the com-
pletion of which c-kit–positive cells were sorted by flow cytometry.
Results: In endomyocardial biopsies, a median number of 2.7 (1.8–4) c-kit–positive
cells/mm2 were found, and this number was even significantly smaller in right
appendage biopsies (1 [0.5–1.8] c-kit–positive cell/mm2, P 5 .01). All of these
c-kit–positive cells co-stained for CD45 and were more specifically identified as mast
cells by their positive staining for the specific tryptase marker. However, none of
the c-kit–positive cells expressed the markers of stemness MDR-1 and Isl-1 or colo-
calized with CD105. Flow cytometry confirmed the small number of c-kit–positive
cells in cultured right atrial appendages.
Conclusion: These data raise a cautionary note on the therapeutic exploitation of car-
diac stem cells in patients with ischemic cardiomyopathy, who may be the elective
candidates for regenerative therapy.
I
n the field of cardiac development, one of the most controversial concepts devel-
oped during the past few years has been the recognition that (in contrast with
a long-standing dogma) the heart is not a terminally differentiated organ but
that it harbors a population of stem cells ensuring the lifelong renewal of cardiomyo-
cytes and the ability to divide further in response to injury.1,2 Aside from the cognitive
implications of such a paradigm for a better understanding of cardiac developmental
biology, this finding was soon recognized to be important for fostering strategies of
regenerative therapies aimed at alleviating the consequences of heart failure. In the
ongoing quest for the ideal cell to be used for reconstituting a functional myocardium,
these cardiac stem cells (CSCs) might become major players because of their 2 major
characteristics: an autologous origin, overcoming the ethical, immunologic, and tech-
nical challenges associated with embryonic stem cells, and a cardiogenic differentia-
tion, potentially leading to the generation of new cardiomyocytes expected to express,
among others, the gap junction proteins required for electromechanical coupling with
those of the host myocardium. As such, these cells should allow the formation of
a functional syncytium, which is a prerequisite for the graft to beat in synchrony
with the remainder of the heart and thus contribute to augment its pump function.
To the present, studies on CSCs have primarily focused on animal models, and few
clinical data are available. The present study was designed to assess whether these
cells could be identified in the myocardium in patients (particularly those with
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ischemic heart disease) in such a way that their subsequent




After informed written consent and board approval were obtained,
percutaneous right ventricular endomyocardial biopsies (EMBs)
were performed during routine follow-up visits of heart transplant
recipients. In another set of experiments, right atrial appendages
were removed after right atrial cannulation during elective coronary
artery bypass grafting (CABG) in patients with chronic ischemic
cardiomyopathy. All samples were fixed in formalin and embedded
in paraffin. Tissue sections (5-mm thick) were subsequently immu-
nostained for the expression of different cell markers.
Immunohistochemistry
Samples were processed as previously described3 using antibodies
recognizing markers of stemness (c-kit, dilution 1/50, Dako,
Trappes, France; MDR-1, 1/250, Proteogenix, Oberhausbergen,
France; Isl-1, 1/50, Developmental Studies Hybridoma Bank,
Iowa City, Iowa), hematopoietic origin (CD45, 1/100, Dako),
mast cells (tryptase, 1/200, Dako), endothelial cells (CD105,
1/100, Abcam, Cambridge, UK), and cardiac lineage (Nkx2.5, 1/50,
R&D, Minneapolis, Minn). Both negative and positive controls
were used to assess the specificity of the labeling. Negative controls
were obtained by replacing primary mouse monoclonal antibodies
against MDR-1, Isl-1, CD45, tryptase, Nkx2.5, and CD105 by nor-
mal mouse serum and rabbit polyclonal antibody against c-kit by
normal rabbit serum. Positive controls were as follows: c-kit–posi-
tive tumor cells in a gastrointestinal stromal tumor; MDR-1–positive
tubules in a human kidney obtained from the normal part of a ne-
phrectomy specimen for cancer; Isl-1–positive nuclei in Langerhans
islet cells obtained from a pancreas removed for neonatal hypogly-
cemia; tryptase-positive mast cells in an inflammatory skin lesion;
CD105-positive endothelial cells in cardiac tissue; and Nkx2.5-
positive nuclei in normal adult cardiac myocytes.
Cell Counts
Whole labeled tissue sections were scanned using an eyepiece grid
with a microscope at 320 magnification. The number of c-kit–pos-
itive cells was normalized per square millimeter to account for the
variable number of examined fields per patient, which in turn re-
flected the variable size of the tissue samples available for analysis.
Combined Immunofluorescence and Confocal
Laser Microscopy
These procedures were performed as previously described.4 In brief,
the rabbit polyclonal anti-c-kit antibody was first incubated and
revealed by using a biotinylated anti-rabbit antibody (Dako) and674 The Journal of Thoracic and Cardiovascular Surgery c Marstreptavidin-cyanin-2 (Amersham, Les Ulis, France) or by using
an Alexa 555-labeled anti-rabbit antibody (Invitrogen, Cergy-Pon-
toise, France); monoclonal antibodies against tryptase or CD45
were then incubated and revealed using a cyanin-3–labeled anti-
mouse antibody, and Nkx2.5 and CD105 antibodies were revealed
using a biotin-labeled antimouse antibody and streptavidin-cya-
nin-2. Double immunofluorescence was assessed with a confocal
laser microscope (Leica, Rueil-Malmaison, France).
Cell Cultures
Three intraoperatively harvested right appendages were cultured
according to previously described techniques developed to grow
CSCs5,13,14 and assessed for the expression of c-kit by flow cytom-
etry. Data were collected with CellQuest software and analyzed with
ModFitLT2.0 software (BD Biosciences, Le-Pont-de-Claix,
France).
Statistics
The results are expressed as means6 1 standard deviation or median
values (interquartile range). Comparison of c-kit–positive cell num-
bers between EMB and right appendage samples was performed by
the Wilcoxon test, and the level of statistical significance was set at
the .05 level.
Results
EMBs were obtained in 32 heart transplant recipients. The
mean ages of these patients and their donors were 45.8 6
11 years and 40.1 6 10 years, respectively. The time since
transplantation was 73.5 6 77 months, and the percentages
of grade 0 and 1A pathologic rejection were 62.5% and
37.5%, respectively. Right appendage tissue was collected
in 18 patients (mean age: 65.36 8.1 years; male/female ratio:
16/2) undergoing elective isolated CABG.
The median number of microscopic fields assessed per pa-
tient was 14 (range: 10.5–17.5) for EMBs and 30 (17–45) for
right appendage biopsies. In EMBs, a median number of 2.7
[1.8;4] c-kit–positive cells/mm2 were found, regardless of the
age of the donor and the time interval between transplantation
and biopsy (Figure 1, A). This number was significantly
smaller in right appendage biopsies (1 [0.5;1.8] c-kit–positive
cell/mm2, P 5 .01 vs EMB, Figure 1, B). Colocalization ex-
periments demonstrated that all these c-kit–positive cells
were of hematopoietic origin, as evidenced by their positive
staining for CD45 (Figure 1, C). Their perivascular location
suggested that the c-kit–positive cells could be mast cells,
and this phenotype was confirmed by a consistently positive
staining for the specific tryptase marker (Figure 1, D). How-
ever, none of the c-kit–positive cells identified in these tissue
samples expressed the markers of stemness (MDR-1, Isl-1),
whereas the antibodies used strongly stained control tissues
(Figure 2, A and B). Furthermore, the c-kit–positive cells
did not colocalize with the cardiac lineage marker Nkx2.5
(Figure 2, C). Likewise, the CD105 marker stained endothe-
lial cells in both EMBs and right atrial biopsies, but there was
no overlay between this staining and the expression of the
stem cell marker c-kit (Figure 2, D). The culture data tendedch 2008
Pouly et al Cardiothoracic TransplantationFigure 1. A, Detection of the c-kit marker
by immunohistochemistry. Two mast cells
(arrows) are identified in the interstitium
of the myocardium in an EMB (3250). B,
Detection of the c-kit marker by immuno-
histochemistry. Mast cell (arrow) is identi-
fied in a right atrial appendage specimen
(3200). C, Mast cell (arrow) co-expresses
c-kit and the hematopoietic lineage marker
CD45 (combined immunofluorescence with
rabbit polyclonal anti-c-kit antibody re-
vealed with cyanin-2 green fluorescence
and mouse monoclonal anti-CD45 antibody
revealed with cyanin-3 red fluorescence)
(3150). D, Mast cell co-expresses c-kit
and the mast cell lineage marker tryptase
(combined immunofluorescence with rab-
bit polyclonal anti-c-kit antibody revealed
with cyanin-2 green fluorescence and
mouse monoclonal anti-tryptase antibody
revealed with cyanin-3 red fluorescence)
(32.000).TXto support the scarcity of c-kit–positive cells in right append-
age tissue because they represented only 0.58% 6 0.67% of
cells identified by flow cytometry after a 3- to 4-week period
of cultures.
Discussion
The major finding of the present study is that cells expressing
the classic markers of stemness are rare in the right append-The Journal of Thorage and septal walls of adult patients, particularly those with
ischemic heart disease, and that their phenotype is consistent
with that of mast cells and not of precursors of the cardiomyo-
cytic lineage.
Methodologic Issues
One major issue raised by CSCs is the multiplicity of markers
that have been described to characterize them. At least 4acic and Cardiovascular Surgery c Volume 135, Number 3 675
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TXFigure 2. A, Anti-MDR-1 immunohisto-
chemistry. In the normal kidney used as
positive control tissue, the MDR-1 antibody
detects a strong signal in the tubules
(3350). B, Anti-islet-1 immunohistochemis-
try. In the neonatal pancreas used as posi-
tive control tissue, islet-1 is expressed in
the nuclei of the Langerhans islets
(3500). C, c-kit–positive mast cells (ar-
rows) do not express the cardiac myocyte
lineage marker Nkx2.5 (arrowheads) (com-
bined immunofluorescence with rabbit
polyclonal anti-c-kit antibody revealed
with cyanin-3 red fluorescence and mouse
monoclonal anti-Nkx2.5 antibody revealed
with cyanin-2 green fluorescence) (3200).
D, c-kit–positive mast cells (arrows) do
not express the endothelial cell lineage
marker CD105 (arrowheads) (combined im-
munofluorescence with rabbit polyclonal
anti-c-kit antibody revealed with Alexa
555-red fluorescence and mouse monoclo-
nal anti-CD105 antibody revealed with
cyanin-2 green fluorescence) (3350).different markers, which are at times mutually exclusive,
have been described: c-kit,5,6 Sca-1,7 side population,8,9
and Isl-1.10 It is difficult to reconcile the multiplicity of these
phenotypic patterns with the limited (if any) self-regenerative
capacity of the heart. Because the CSC population is not char-
acterized in a more consistent way, we selected to identify
these cells on the basis of c-kit, the receptor of stem cell fac-
tor, because experimentally clonogenic c-kit–positive cells
have been reported to feature a greater ability to generate
myocardial cells.5
Our results show that there are few c-kit–positive cells in
the right septal wall of presumably normal adult hearts (those
used for transplantation) and that this number is still lower in
patients undergoing CABG for ischemic heart disease, who
are actually better representatives of the target population676 The Journal of Thoracic and Cardiovascular Surgery c Mafor regenerative therapy. The perivascular location of these
c-kit–positive cells was consistent with a mast cell pheno-
type, which was confirmed by their expression of the panhe-
matopoietic marker CD45, the mast cell-specific marker
tryptase (and an additional positive staining for toluidine
blue; data not shown). By itself, this finding is not unexpected
because the right appendage has been shown to harbor 0.5%
to 1.5% of mast cells,11 and both cyclosporine and FK506
have been reported to up-regulate the expression of c-kit on
a mast cell line,12 which could account for the greater number
of the c-kit–positive cells in our EMB-derived tissue samples.
The important observation is that none of these c-kit–positive
cells expressed any of the other tested markers of stemness
(MDR-1 and Isl-1) or of the more specific cardiac differenti-
ation pathway (Nkx 2.5), thereby raising serious doubtsrch 2008
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in the adult myocardium. These findings are consistent with
those of Yamabi and colleagues,13 who reported that c-kit–
positive cells isolated from human fetal hearts were negative
for cardiac markers. Their results differ from the experimen-
tal observation that cardiac c-kit–positive cells are lineage-
negative but overall fit the paradigm that these progenitors
are rare, on the order of 1 per 1 3 104 myocytes.14 Whether
the hematopoietic c-kit–positive cells that we have identified
normally reside in cardiac niches or dynamically migrate
from the bone marrow cannot be determined from the present
study. Likewise, our findings do not exclude that an initially
present pool of CSCs was subsequently exhausted because of
senescence or after its mobilization for repairing ischemic
injuries because cardiac failure in humans has been reported
to cause a 10-fold increase in the number of dividing cardio-
myocytes compared with healthy hearts.15 This compensa-
tory phenomenon may have emptied the reservoir of CSCs.
The hypothesis that cardiac progenitors may disappear over
time is also supported by the finding made in tissue samples
retrieved during pediatric heart operations that Isl-1–positive
cells have only been detected up to the age of 8 weeks.10
Comparison With Previous Studies
Studies performed in rat,6 dog,5 and pig16 have demonstrated
that CSCs differentiated into cardiomyocytes after engraft-
ment into infarcted myocardium, reduced infarct size, atten-
uated remodeling, and improved left ventricular function. In
contrast, human data are limited to 3 clinical studies. In the
study by Urbanek and colleagues,17 samples were retrieved
from the hypertrophied left ventricular wall of patients under-
going aortic valve surgery, which makes the comparison dif-
ficult with our data. Conversely, the study by Messina and
colleagues18 is more similar to ours in that it entailed deriva-
tion of human tissue from atrial or ventricular biopsy speci-
mens taken during cardiac operations and subsequent
culture that resulted in self-adherent clusters called cardio-
spheres. These cardiospheres expressed endothelial and
stem cell markers (including c-kit), and cells derived from
them displayed morphologic and phenotypical patterns char-
acteristic of cardiomyocytes. A similar approach was subse-
quently described by Smith and colleagues,16 who used
human right ventricular biopsy specimens to grow cardio-
spheres made of a mix population of cardiac progenitors,
fibroblasts, and mesenchymal cells. These cardiospheres
were primarily defined by a consistent expression of c-kit
and CD105, which contrasts with our finding that these 2
markers were not coexpressed by the same cells and suggests
that CD105 expression in cardiospheres may have reflected
a contamination by endothelial cells. Although the putative
CSCs did not spontaneously beat unless they were cocultured
with rat cardiomyocytes in these 2 studies, their injection of
the border zones of acute myocardial infarction in immuno-
deficient mice resulted in improved function and histologicThe Journal of Thorpatterns of cardiac regeneration. Altogether, these data
have raised the appealing hypothesis that CSCs could be
retrieved from an EMB16 or pharmacologically mobilized
by growth factors5 and, after in vitro expansion, reinjected
to effect myocardial regeneration.
However, the results of these studies should be interpreted
cautiously because of the possibility of phenotypic changes
induced by repeat passages, which could explain why the an-
tigen expression pattern of these cultured cells was different
from that of the unprocessed cells examined in the present
study and possibly closer to the biological reality. Further-
more, the fact that CSCs only acquired their cardiomyocyte
phenotype after co-cultures with rat cardiomyocytes makes
it difficult to exclude the possibility that the cardiomyocytic
differentiation of the engrafted cardiosphere-derived CSCs
was not a mere consequence of fusion events.7 It is notewor-
thy that the patient demographics were not clearly detailed in
any of the above mentioned studies (in one study, it was sim-
ply reported that the patients’ ages ranged from 1 month to 80
years18).
Study Limitations
This study was primarily based on immunostaining, which
may always be fraught with technical artifacts, particularly
when colocalization experiments are performed. Efforts
were made to minimize these shortcomings with the use of
confocal microscopy. Furthermore, the unequivocal expres-
sion of the cardiac markers Nkx2.5, MDR-1, and Isl-1 in
our positive controls makes it unlikely that these markers
would have been missed if they had been expressed by the
c-kit–positive cells. We also acknowledge that deriving quan-
titative data from immunohistochemical observations may
not be accurate, but it is unlikely that it may have led to a gross
underestimation of the number of CSCs, given our method of
counting. Second, one could argue that we did not test the
whole set of stemness or cardiac differentiation markers.
We did not assess the expression of Sca-1 because the cardiac
differentiation of Sca-1–positive cells requires exposure to 5-
azacytidine,7 which is clinically irrelevant. Furthermore, the
ability of cells expressing this marker to give rise to cardio-
myocytes is 6 times less than that of c-kit–positive cells.5
We did not screen the tissue samples for GATA-4 or MEF-
2 because of the lack of specific monoclonal antibodies that
were required for the co-staining experiments with our anti-
c-kit polyclonal antibody. A third limitation of the results
obtained in the surgical group of patients is that sampling
was performed in the right atrium. This was intentionally
done to mimic a clinical scenario whereby CSCs would be
harvested by an EMB and does not allow the exclusion of
the presence of resident cardiac progenitors in other areas
of the heart, for which the accessibility would then be more
technically challenging. Finally, one could argue that we
only provided a snapshot of the c-kit–positive cell content
in biopsies without subsequent sorting and single cell clonalacic and Cardiovascular Surgery c Volume 135, Number 3 677
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these cells could be expanded in vitro. This is conceivable,
although not supported by our flow cytometry data that
demonstrated only a small proportion of c-kit–positive cells
after culture. Given the minute amount of starting materials,
sorting of the candidate cells and their expansion (without
loss of the cardiac differentiation potential) under Good
Manufacturing Practice are likely to be technically challeng-
ing and time-consuming procedures, notwithstanding the de-
lay in onset of cell therapy, which may be a concern in these
often critically ill patients. The individual variability in cell
functionality and the cost of customized quality controls
may further complicate the clinical practicality of this pa-
tient-specific approach.
Conclusions
Cell-based interventions can be oriented toward paracrine or
structural objectives. The paracrine objective implies that the
transplant has to primarily supply a missing mediator, such as
insulin or dopamine in the cases of diabetes and Parkinson
disease, respectively. In these settings, the replacement cells
must not necessarily adopt a phenotype that fully matches
that of the diseased cells as long as the missing substance
is appropriately secreted. Conversely, the structural objective
implies that the grafted cells ensure the true regeneration of
a dead tissue. In this case, an optimal outcome can only be
expected if the grafted cells adopt the phenotype of the cells
they are intended to replace. This is especially true in the con-
text of heart failure in which improvement of left ventricular
function requires that large areas of dysfunctional myocar-
dium be repopulated by new cells featuring a contractile
activity and able to electromechanically couple with the
host cardiomyocytes. The limited plasticity of adult cells19,20
and the results of fetal cardiomyocyte transplantation suggest
that cells that recapitulate the developmental cardiomyogenic
pathway are the best candidates for generating new myocar-
dium.21,22 Although the use of CSCs seems appealing in this
setting, the present results raise a cautionary word about the
possibility of therapeutically exploiting these cells in patients
who might need them most and call for additional investiga-
tion of adult or embryonic stem cells capable of featuring
a cardiomyogenic differentiation potential after intramyocar-
dial engraftment.
We acknowledge the expert secretarial assistance of Emilie
Floc’h.
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